GoldenGolden
Mekonos

Mekonos

Mekonos is a company that creates cell-engineering platforms

All edits by  Daniel Frumkin 

Edits on 2 Dec, 2020
Daniel Frumkin"added artice"
Daniel Frumkin edited on 2 Dec, 2020
Edits made to:
Description (+60 characters)
Article (+1045 characters)
Topic thumbnail

Mekonos

Mekonos is a company that creates cell-engineering platforms

Article

Mekonos is a company that has created a platform that allows cell and gene therapies to be more accessible. The company was founded by Anil Narsimha, Greg Sitters, and Steven Banerjee in 2017, in San Francisco, California, United States.

Mekonos is responsible for developing over nine hundred therapeutic candidates, and expect roughly forty of them to be approved by the end of 2022. They developed their therapeutics through their platform solution, Iris, which is a System-on-a-Chip that allows for automated deliveries and precision for multiplexing.

Iris is a pharmaceutical and biotechnological platform that allows for targeted delivery and dose control of gene therapeutics that includes nucleic acids, protein complexes, and small molecules, and cell treatments such as primary, immune, and stem cells.

Microfluidics, micro-electro-mechanical systems, and chemistry to expand their catalogue of payloads and cell types. Their various methods of expansion allows Mekonos to scale their silicon technology for drug discover and development.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.